Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML).

BL-8040 is a short peptide, high-affinity antagonist of CXCR4 chemokine receptor reported to be involved in tumour progression, angiogenesis, metastasis and cell survival.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multi-centre, single arm, open-label BATTLE trial will investigate the safety, tolerability, relapse-free survival and minimal residual disease status of the combination as a maintenance treatment.

Approximately 60 intermediate and high-risk patients who experienced a complete response (CR) after treatment with induction and consolidation therapy will be enrolled into the trial.

“We are hopeful that combining atezolizumab with BL-8040 will demonstrate the potential to establish a new treatment for AML patients that would extend the duration of remission following induction treatment.”

BioLineRx CEO Philip Serlin said: “The BATTLE study is the first study under our collaboration in hematologic malignancies, and we are hopeful that combining atezolizumab with BL-8040 will demonstrate the potential to establish a new treatment for AML patients that would extend the duration of remission following induction treatment, in particular for patients for whom stem-cell transplantation is inappropriate.”

Planned to be conducted at 22 sites in the US, Europe and Israel, the trial’s primary endpoint is assessment of the combination’s ability to prolong relapse-free survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The impact of the therapy on minimal residual disease, various immunological parameters and potential biomarkers will also be monitored.

In September last year, BioLineRx and Genentech entered cancer immunotherapy collaboration to evaluate the combination in different Phase Ib/II trials for various types of cancer.

Under this partnership, the firms intend to launch additional combination trials by the end of this year.